20 05, 2025 UGT1A1 & DPYD: Safer chemotherapy starts with genotyping UGT1A1 & DPYD: Safer chemotherapy starts with genotyping Nachrichten, Shooting Cancer UGT1A1 & DPYD: Safer chemotherapy starts with genotyping adlitterio663392025-05-20T08:47:15+02:00 Mehr erfahren
13 05, 2025 Shooting Cancer Highlights – Focus periodico su approvazioni e disponibilità di nuove terapie oncologiche a bersaglio molecolare Shooting Cancer Highlights – Focus periodico su approvazioni e disponibilità di nuove terapie oncologiche a bersaglio molecolare Shooting Cancer Shooting Cancer Highlights – Focus periodico su approvazioni e disponibilità di nuove terapie oncologiche a bersaglio molecolare adlitterio663392025-05-13T10:28:55+02:00 Mehr erfahren
10 01, 2025 Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology adlitterio663392025-01-10T15:00:06+01:00 Mehr erfahren
11 07, 2024 Shooting Cancer Highlights – Periodic Focus on regulatory status of new targeted therapies in oncology adlitterio663392024-07-11T14:10:47+02:00 Mehr erfahren
14 05, 2024 Shooting Cancer Highlights – Focus periodico su approvazioni e disponibilità di nuove terapie oncologiche a bersaglio molecolare adlitterio663392024-05-14T14:49:14+02:00 Mehr erfahren
21 12, 2023 Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology – November 2023 adlitterio663392023-12-21T10:08:16+01:00 Mehr erfahren
28 06, 2023 Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – April and May 2023 adlitterio663392023-06-28T10:28:18+02:00 Mehr erfahren
1 04, 2023 Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology – February and March 2023 adlitterio663392023-06-28T10:54:57+02:00 Mehr erfahren
2 03, 2023 Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – January 2023 adlitterio663392023-03-02T10:17:25+01:00 Mehr erfahren
11 01, 2023 Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – November and December 2022 adlitterio663392023-01-11T12:15:44+01:00 Mehr erfahren
